![<?echo $_SERVER['SERVER_NAME'];?>](/template/twentyseventeen/skin/images/header.jpg)
The U.S. Institute of Nuclear Medicine said on July 1 that the newly published "Journal of Nuclear Medicine" reported a new type of optical imaging technology called Cerenkov luminescence imaging. According to the author of the article, new technologies are expected to help people diagnose and treat cancer and other diseases, as well as develop radiopharmaceuticals more quickly and more effectively.
The head of research, Dr. Jane Grimm, professor of the Sloan-Kettering Memorial Cancer Center, said that the new multi-channel imaging agents and technologies are at the forefront of research in the field of medical imaging science, which may open up new ways for new optical imaging to enter clinical applications. The Grimm team believes that his own research belongs to those who first discussed the application of Cerenkov radiation to medical imaging. It is reported that scientists from the University of California and Stanford University participated in the study.
When light travels in water, its speed will slow down. At this time, a particle whose speed exceeds the speed of light is like a sonic boom that breaks through a sound barrier. It produces a "shock wave" (or "shock wave") that emits blue visible light. This phenomenon is called Cherenkov radiation.
Optical imaging is a molecular imaging process. During this process, luminescent molecules designed for attachment to specific cells and molecules are injected into human blood and can be detected by optical imagers. In general, these luminescent molecules need to be activated by an external light source or biological means in order to facilitate the operation of the optical imager.
In the new optical imaging technology, since the light generated by the Cerenkov imaging is derived from radiation, it is no longer necessary to use an external light source for illumination. Glinm believes that this combination of optical imaging and nuclear medicine represents a new approach to medical imaging. He also stated that many nuclear tracers are currently approved for use in clinical medicine. The Cerenkov luminescence imaging system consisting of optical imaging systems can be used very quickly, which is very different from fluorescent dyes.
In the study, scientists evaluated several radionuclides that may be used in Cerenkov's luminescence imaging system. They visualized the mice with tumors using Cherenkov's luminescence imaging system and Positron Emission Tomography (PET). The results showed that the Cerenkov luminescence imaging system was able to take radioactive traces into the body. Visualization.
The researchers said that Cherenkov's luminescence imaging technology uses a light isotope that was previously impossible to visualize, that is, it can image radioactive tracers that neither emit positrons nor emit gamma rays. This capability is currently nuclear. Imaging methods do not have. In addition, optical imaging technology will facilitate endoscopic examination and surgery because it can visualize lesions in the tumor and provide real-time information for surgery.
The head of research, Dr. Jane Grimm, professor of the Sloan-Kettering Memorial Cancer Center, said that the new multi-channel imaging agents and technologies are at the forefront of research in the field of medical imaging science, which may open up new ways for new optical imaging to enter clinical applications. The Grimm team believes that his own research belongs to those who first discussed the application of Cerenkov radiation to medical imaging. It is reported that scientists from the University of California and Stanford University participated in the study.
When light travels in water, its speed will slow down. At this time, a particle whose speed exceeds the speed of light is like a sonic boom that breaks through a sound barrier. It produces a "shock wave" (or "shock wave") that emits blue visible light. This phenomenon is called Cherenkov radiation.
Optical imaging is a molecular imaging process. During this process, luminescent molecules designed for attachment to specific cells and molecules are injected into human blood and can be detected by optical imagers. In general, these luminescent molecules need to be activated by an external light source or biological means in order to facilitate the operation of the optical imager.
In the new optical imaging technology, since the light generated by the Cerenkov imaging is derived from radiation, it is no longer necessary to use an external light source for illumination. Glinm believes that this combination of optical imaging and nuclear medicine represents a new approach to medical imaging. He also stated that many nuclear tracers are currently approved for use in clinical medicine. The Cerenkov luminescence imaging system consisting of optical imaging systems can be used very quickly, which is very different from fluorescent dyes.
In the study, scientists evaluated several radionuclides that may be used in Cerenkov's luminescence imaging system. They visualized the mice with tumors using Cherenkov's luminescence imaging system and Positron Emission Tomography (PET). The results showed that the Cerenkov luminescence imaging system was able to take radioactive traces into the body. Visualization.
The researchers said that Cherenkov's luminescence imaging technology uses a light isotope that was previously impossible to visualize, that is, it can image radioactive tracers that neither emit positrons nor emit gamma rays. This capability is currently nuclear. Imaging methods do not have. In addition, optical imaging technology will facilitate endoscopic examination and surgery because it can visualize lesions in the tumor and provide real-time information for surgery.